Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide

Vaccine

Volumn 30, Issue 1, 2011, Pages 9-13

  Sheen, Tamsin R ^a   Cavaco, Courtney K ^a   Ebrahimi, Celia M ^a   Thoman, Marilyn L ^b   Sanderson, Sam D ^c   Morgan, Edward L ^b   Doran, Kelly S ^a,d  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

C5a agonist; CA MRSA; EP67; Innate immunity; PMN; Staphylococcus aureus

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; EP 67; IMMUNOSTIMULATING AGENT; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CONFORMATION; FEMALE; HOST RESISTANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; KNOCKOUT MOUSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SKIN NECROSIS; ANIMAL; DISEASE MODEL; DRUG POTENTIATION; IMMUNOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; STAPHYLOCOCCAL SKIN INFECTION; TREATMENT OUTCOME;

ANIMALS; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOLOGIC FACTORS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; PEPTIDES; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

EID: 84858600671     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.054     Document Type: Article

References (23)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339(August (8)):520-32.
2. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298(October (15)):1763-71.
3. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009;119(September (9)):2464-74.
4. Kennedy AD, Otto M, Braughton KR, Whitney AR, Chen L, Mathema B, et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci U S A 2008;105(January (4)):1327-32.
5. Taylor SM, Sherman SA, Kirnarsky L, Sanderson SD. Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations. Curr Med Chem 2001;8(May (6)): 675-84.
6. Vogen SM, Paczkowski NJ, Kirnarsky L, Short A, Whitmore JB, Sherman SA, et al. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation. Int Immunopharmacol 2001;1(November (12)):2151-62.
7. Morgan EL, Morgan BN, Stein EA, Vitrs EL, Thoman ML, Sanderson SD, et al. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine 2009;28(December (2)):463-9.
8. Morgan EL, Thoman ML, Sanderson SD, Phillips JA. A novel adjuvant for vaccine development in the aged. Vaccine 2010;28(December (52)):8275-9.
9. Pattee PA. Distribution of Tn551 insertion sites responsible for auxotrophy on the Staphylococcus aureus chromosome. J Bacteriol 1981;145(January (1)):479-88.
10. Highlander SK, Hulten KG, Qin X, Jiang H, Yerrapragada S, Mason Jr EO, et al. Subtle genetic changes enhance virulence of methicillin resistant and sensitive Staphylococcus aureus. BMC Microbiol 2007;7:99.
11. Phillips JA, Morgan EL, Dong Y, Cole GT, McMahan C, Hung CY, et al. Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. Bioconjug Chem 2009;20(October (10)): 1950-7.
12. Bunce C, Wheeler L, Reed G, Musser J, Barg N. Murine model of cutaneous infection with gram-positive cocci. Infect Immun 1992;60(July (7)): 2636-40.
13. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6Gspecific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 2008;83(January (1)):64-70.
14. Banerjee A, Kim BJ, Carmona EM, Cutting AS, Gurney MA, Carlos C, et al. Bacterial pili exploit integrin machinery to promote immune activation and efficient blood-brain barrier penetration. Nat Commun 2011;2:462.
15. van Sorge NM, Ebrahimi CM, McGillivray SM, Quach D, Sabet M, Guiney DG, et al. Anthrax toxins inhibit neutrophil signaling pathways in brain endothelium and contribute to the pathogenesis of meningitis. PLoS ONE 2008;3(8):e2964.
16. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78(March (3)):206-9.
17. Tvinnereim AR, Hamilton SE, Harty JT. Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens. J Immunol 2004;173(August (3)):1994-2002.
18. Stephens-Romero SD, Mednick AJ, Feldmesser M. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect Immun 2005;73(January (1)):114-25.
19. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355(August (7)):666-74.
20. Li M, Cheung GY, Hu J, Wang D, Joo HS, Deleo FR, et al. Comparative analysis of virulence and toxin expression of global community-associated methicillinresistant Staphylococcus aureus strains. J Infect Dis 2010;202(December (12)):1866-76.
21. Molne L, Verdrengh M, Tarkowski A. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun 2000;68(November (11)):6162-7.
22. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am 2009;23(March (1)):17-34.
23. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Said-Salim B, Porcella SF, et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 2005;175(September (6)):3907-19.